I do think it's smart to get a question or two submitted. On the other hand I fear a full frontal assault from overzealous posters that leave the Recovery folks thinking Leronlimab could be as snake-oily as many of the submitters could come across.
To that point, maybe a few people could coordinate on generating a couple questions to put forth. For instance, trying to get CD10/12 results into a question is a delicate matter because both trials had some problems. To get someone to see the promising portions of those studies you'd need to spend more time than a quick question provides. There'll likely be a ton of questions and cutting through the noise will be difficult if it feels like retail investors are there to pump their investment versus someone with an idea for a valid scientific approach.
Here are a couple quick questions that could almost certainly be molded into something more succinct, neutral, and impactful by others on the board like Ohm, Plotinus, Katangolo, Ken, etc.
One promising area of drug development lately has been monoclonal antibodies that target CCR5, which plays a key role in immune regulation. CCR5 is implicated as a potential treatment path in oncology, hiv, and many other disease states. Will the program be studying or including any CCR5 mabs like Miraviroc from Pfizer or Leronlimab from Cytodyn in the Recovery program?
In the rush to react to Covid 19 many drugs were rushed into trials that ultimately failed for myriad reasons. One drug I find particularly compelling is the CCR5 antagonist Leronlimab, which had two Covid studies and one long Covid trial during the height of the pandemic. The unknowns about covid, and what it would take to treat it, seem to have led to underpowered trial designs that ultimately left more questions than answers. But despite that, there was some very compelling data from each trial that appear to suggest Leronlimab as a perfect candidate for more rigorous study. Is Leronlimab a targeted treatment for the Recovery Program?
To that point, maybe a few people could coordinate on generating a couple questions to put forth. For instance, trying to get CD10/12 results into a question is a delicate matter because both trials had some problems. To get someone to see the promising portions of those studies you'd need to spend more time than a quick question provides. There'll likely be a ton of questions and cutting through the noise will be difficult if it feels like retail investors are there to pump their investment versus someone with an idea for a valid scientific approach.
Here are a couple quick questions that could almost certainly be molded into something more succinct, neutral, and impactful by others on the board like Ohm, Plotinus, Katangolo, Ken, etc.
One promising area of drug development lately has been monoclonal antibodies that target CCR5, which plays a key role in immune regulation. CCR5 is implicated as a potential treatment path in oncology, hiv, and many other disease states. Will the program be studying or including any CCR5 mabs like Miraviroc from Pfizer or Leronlimab from Cytodyn in the Recovery program?
In the rush to react to Covid 19 many drugs were rushed into trials that ultimately failed for myriad reasons. One drug I find particularly compelling is the CCR5 antagonist Leronlimab, which had two Covid studies and one long Covid trial during the height of the pandemic. The unknowns about covid, and what it would take to treat it, seem to have led to underpowered trial designs that ultimately left more questions than answers. But despite that, there was some very compelling data from each trial that appear to suggest Leronlimab as a perfect candidate for more rigorous study. Is Leronlimab a targeted treatment for the Recovery Program?
31
